Business Wire

Radisys Introduces White Box Combo PON Optical Line Terminals for Next-Gen FTTX Networks

13.7.2021 15:00:00 EEST | Business Wire | Press release

Share

Radisys® Corporation, a global leader of open telecom solutions, today introduced the Radisys Combo PON Optical Line Terminal (OLT) as part of the Radisys Connect Open Broadband portfolio for broadband service providers. The complete family of Radisys OLTs includes 16 and 32-port versions—a variant of which is the Radisys white box Combo PON OLT that supports both G-PON (2.488 Gbps downstream / 1.244 Gbps upstream) and XGS-PON (10 Gbps symmetrical) within the same PON port of the OLT. The white box OLTs are based on the VOLTHA/SEBA reference architecture and are field-hardened and scaled for commercial deployments today.

News Highlights

  • A growing number of global service providers are moving forward with XGS-PON as their next-generation PON technology of choice. Analyst firm Dell-Oro Group predicts XGS-PON will be the favored PON technology for the future.
  • Radisys’ Combo PON OLT allows broadband providers to take advantage of pervasive G-PON technology while giving them a flexible upgrade path to scale up and rollout XGS-PON deployments without costly rip and replace.
  • Radisys’ Combo PON OLT is an open, flexible, highly scalable telco-grade white box designed to address service providers’ key needs.
    • Full PON port flexibility enables G-PON, XGS-PON or Combo PON (G-PON and XGS-PON) on any port on the same platform.
    • Open architecture delivers datacenter-driven cost efficiencies and high port densities, making it suitable for residential, cloud and enterprise services to simplify deployments and reduce operating expenses.
    • Compatibility with any ONF VOLTHA-based software, including Radisys’ Connect Broadband Access Controller (CBAC) software, allows service providers to scale hardware up or down while the management software and all other Connect Open Broadband components remain intact.
    • Flexibility to deploy virtualized functions either in a distributed fashion running within the OLT CPU, or as a centralized function hosted on an external server or a public or private cloud.
  • Radisys’ Combo PON OLTs are part of the Connect Open Broadband product suite, which includes open and disaggregated software, hardware and management.
  • The complete family of Radisys OLTs also includes the 16 and 32-port OLTs. The Radisys 32 port G-PON OLT (RLT-3200G) was recently certified for VOLTHA v2.8 through Open Networking Foundation’s Continuous Certification Program.

“Radisys’ Combo PON OLTs give broadband providers an optimal economic advantage with the flexibility to use both G-PON and XGS-PON in their networks and through a reduction in space and power consumption,” said Harris Razak, senior vice president of Broadband Access, Radisys. “All products in the Connect Open Broadband portfolio utilize the same management system and controlling software, allowing our provider customers to choose the features and capacity they want while keeping other network elements the same, lowering their total cost of ownership and optimizing their Capex and Opex.”

“We are pleased that Radisys’ 32-port G-PON OLT has been named a certified VOLTHA product within the ONF Continuous Certification Program. This certification, along with the introduction of the Radisys Combo PON OLT with support for VOLTHA/SEBA, offers broadband service providers with greater solution choices for their FTTX deployments,” said Guru Parulkar, ONF Executive Director. “As an ONF Partner Member, Radisys has been instrumental in the development of ONF open reference designs as well as the commercialization of ONF-based solutions. The Continuous Certification Program ensures that service providers can easily identify certified products for specific ONF projects within a vibrant ecosystem of vendors delivering and deploying ONF open source platforms.”

About Radisys

Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nereus for Radisys
Lori Mesecke, +1-503-459-9150
lmesecke@nereus-worldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye